Crossject : Avancements réglementaires et besoin de financement au cœur des attentions à court terme
>Besoin de financement à court terme - Crossject a publié hier ses chiffres au titre de l’exercice 2023. Les produits d’exploitation progressent de 32% à 12.8 M€ notamment grâce à l’augmentation des frais de R&D facturés à la BARDA (6.7 M€ contre 1.8 M€ en 2022). Les charges d’exploitation demeurent relativement stables à 25.1 M€ pour une perte opérationnelle de -12.3 M€.La trésorerie à fin 2023 s’élevait à 2.3 M€, celle-ci ne prend pas en compte la 1ère tranche...Crossject SA is a France-based company that designs and develops medical injection systems. The Company specializes in needle-free, pre-filled, single-use injection systems for intradermal, subcutaneous and intramuscular applications for pharmaceutical companies. Is also has a pipeline and three drugs in the preclinical or clinical phase of research. The Company's products, which are based on well-known injectable drugs (chemicals and biologics), are designed to enhance patients' safety, compliance and comfort. Crossject's first ZENEO SUPERGENERIC product is expected to reach the market in the year 2015. The Company has industrial partnerships with Hirtenberger and Recipharm.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.